1 to 7 of 7 literature results

• Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

  BACKGROUND: Amputations in people with type 2 diabetes mellitus substantially impair their quality of life and impose high costs on health-care system…

  Authors: Kushwin Rajamani, Peter G Colman, Li Ping Li, James D Best, Merryn Voysey, Michael C D'Emden, Markku Laakso, John R Baker, Anthony C Keech, FIELD study investigators

  Source: Lancet. 2009 May 23

  View Full Text

• Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

  BACKGROUND: Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to ass…

  Authors: A C Keech, P Mitchell, P A Summanen, J O'Day, T M E Davis, M S Moffitt, M-R Taskinen, R J Simes, D Tse, E Williamson,…

  Source: Lancet. 2007 Nov 17

  View Full Text

• Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  OBJECTIVE: We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndro…

  Authors: Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael D'Emden, Dana Tse, Marja-Riitta Taskinen, Christian Ehnholm, Anthony Keech, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators

  Source: Diabetes care. 2009 Mar

  View Full Text

• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  BACKGROUND: Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenab…

  Authors: A Keech, R J Simes, P Barter, J Best, R Scott, M R Taskinen, P Forder, A Pillai, T Davis, P Glasziou,…

  Source: Lancet. 2005 Nov 26

  View Full Text

• The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

  BACKGROUND: Fibrates correct the typical lipid abnormalities of type 2 diabetes mellitus, yet no study, to date, has specifically set out to evaluate …

  Authors: FIELD Study Investigators

  Source: Cardiovascular diabetology. 2004 Dec 1

  View Full Text

• Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.

  OBJECTIVE: The purpose of this study was to determine fenofibrate-induced changes in plasma high-density lipoprotein cholesterol (HDL-C), apolipoprote…

  Authors: Marja-Riitta Taskinen, David R Sullivan, Christian Ehnholm, Malcolm Whiting, Diana Zannino, R John Simes, Anthony C Keech, Philip J Barter, FIELD study investigators

  Source: Arteriosclerosis, thrombosis, and vascular biology. 2009 Jun

  View Full Text

• Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

  OBJECTIVE: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary…

  Authors: R Scott, J Best, P Forder, M-R Taskinen, J Simes, P Barter, A Keech, FIELD Study Investigators

  Source: Cardiovascular diabetology. 2005

  View Full Text